Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 09, 2004. The report details changes in directors' interests regarding Ordinary Shares and American Depositary Shares (ADSs) held within employee trusts.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transactions and trust administration rather than financial performance metrics.
Material Changes
The following share transactions were reported for December 2004:
- December 07: Abacus (GSK) Trustees Limited transferred 12,648 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- December 08: Abacus (GSK) Trustees Limited converted 9,791,588 Ordinary Shares into 4,895,794 ADSs.
- December 08: The converted ADSs were sold at a price of US$43.73 per ADS.
- December 08: Abacus Corporate Trustee Limited (GSK US Trust) purchased 4,895,794 ADSs at US$43.73 per ADS.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that specific directors (Dr. J-P Garnier, Dr. T Yamada, and Mr. J D Coombe) hold interests in the GSK Trust and GSK US Trust as potential beneficiaries alongside other employees.
Investor Verification Points
- Verify the impact of the 4,895,794 ADS transactions on the company's total share count and treasury holdings.
- Confirm the current status of the GSK Trust and GSK US Trust regarding director beneficial ownership.
- Review the full annual report (Form 20-F) for comprehensive financial data, as this filing is limited to director interest changes.